Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 2: Immunotherapy in Lung Cancer-Which Option for Advanced Disease?

Video Transcription

Video Summary

Jibum Lee from Yonsei Cancer Center discusses immunotherapy for advanced non-small cell lung cancer (NSCLC), focusing on the importance of molecular testing for genomic alterations like EGFR mutations and PD-L1 expression. The NCCN guidelines recommend a broad molecular panel for adenocarcinoma and PD-L1 testing for all histologies. Lee reviews pivotal trials, such as Keynote 189 and 407, highlighting the efficacy of pembrolizumab plus chemotherapy, which demonstrates improved overall survival and progression-free survival, particularly in patients with high PD-L1 expression. The presentation also covers different immunotherapy regimens, including monotherapy and combinations with chemotherapy, and the impact of genomic alterations on treatment decisions. Lee emphasizes the need for personalized treatment plans, considering factors like PD-L1 levels, disease progression, and patient-specific attributes, and stresses the importance of monitoring for immune-related adverse events. The talk concludes by encouraging ongoing exploration of strategies to overcome resistance and refine second-line treatment approaches.

Asset Subtitle

Jii Bum (Joy) Lee, MD, PhD

Keywords

immunotherapy

non-small cell lung cancer

molecular testing

pembrolizumab

PD-L1 expression

personalized treatment